Veraxa Biotech Holding AG (VRXAW) Non-Current Deferred Tax Liability (2024 - 2025)
Veraxa Biotech Holding AG (VRXAW) posted quarterly Non-Current Deferred Tax Liability of $18.1 million for Q4 2025, up 4.37% year-over-year from $17.3 million in Q4 2024, and up 4.37% quarter-over-quarter from $17.3 million in Q4 2024.
Veraxa Biotech Holding AG (VRXAW) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Veraxa Biotech Holding AG (VRXAW) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $18.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 4.37% year-over-year to $18.1 million; the TTM figure through Dec 2025 stood at $18.1 million (up 4.37% YoY), while the FY2025 annual figure was $18.1 million, up 4.37% from the prior year.
- Non-Current Deferred Tax Liability climbed to $18.1 million in Q4 2025 per VRXAW's latest filing, from $17.3 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $18.1 million in Q4 2025 and bottomed at $17.3 million in Q4 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.07 Mn |
| Dec 31, 2025 | 18.07 Mn |
| Dec 31, 2024 | 17.31 Mn |
| Dec 31, 2024 | 17.31 Mn |